Apoptosis Signaling in Tumor Therapy

Abstract: Apoptosis, the cell's intrinsic program to death, plays a central role in physiological growth control and regulation of tissue homeostasis. Tipping the balance between cell death and proliferation in favor of cell survival may result in tumor formation. Also, killing of cancer cells by cytotoxic therapies currently used for treatment of cancer, for example, chemotherapy, γ‐irradiation, immunotherapy, or suicide gene therapy, largely depends on activation of apoptosis programs in cancer cells. Accordingly, failure to undergo apoptosis in response to anticancer therapy may result in cancer resistance. Further insights into the mechanisms regulating apoptosis in response to anticancer therapy and how cancer cells evade cell death may provide novel opportunities for drug development.

[1]  Y. Lazebnik,et al.  Caspases: enemies within. , 1998, Science.

[2]  M. Peter,et al.  The death effector domain protein family , 2003, Oncogene.

[3]  S. Fulda,et al.  Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer , 2001, Oncogene.

[4]  S. Fulda,et al.  Deficient activation of the CD95 (APO-1/Fas) system in drug-resistant cells , 1997, Leukemia.

[5]  D. Altieri.  Validating survivin as a cancer therapeutic target , 2003, Nature Reviews Cancer.

[6]  P. Vandenabeele,et al.  The role of mitochondrial factors in apoptosis: a Russian roulette with more than one bullet , 2002, Cell Death and Differentiation.

[7]  A. Ashkenazi,et al.  Apo2L/TRAIL and its death and decoy receptors , 2003, Cell Death and Differentiation.

[8]  S. Fulda,et al.  Metabolic inhibitors sensitize for CD95 (APO-1/Fas)-induced apoptosis by down-regulating Fas-associated death domain-like interleukin 1-converting enzyme inhibitory protein expression. , 2000, Cancer research.

[9]  W. El-Deiry,et al.  Cell surface Death Receptor signaling in normal and cancer cells. , 2003, Seminars in cancer biology.

[10]  G. Salvesen,et al.  Apoptosis: IAP proteins: blocking the road to death's door , 2002, Nature Reviews Molecular Cell Biology.

[11]  Marcel Leist,et al.  Four deaths and a funeral: from caspases to alternative mechanisms , 2001, Nature Reviews Molecular Cell Biology.

[12]  S. Fulda,et al.  Molecular determinants of apoptosis induced by cytotoxic drugs , 1998, Klinische Padiatrie.

[13]  I. Herr,et al.  Involvement of the CD95 (APO–1/Fas) receptor/ligand system in drug–induced apoptosis in leukemia cells , 1996, Nature Medicine.

[14]  F. Behm,et al.  Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN , 2000, Nature Medicine.

[15]  R. Davis,et al.  Signal Transduction by the JNK Group of MAP Kinases , 2000, Cell.

[16]  P. Krammer,et al.  Tumor Immunology , 2018, Medical Immunology.

[17]  S. Nagata.  Apoptotic DNA fragmentation. , 2000, Experimental cell research.

[18]  W. Park,et al.  Inactivating mutations of caspase-8 gene in colorectal carcinomas. , 2003, Gastroenterology.

[19]  F. Brasseur,et al.  A CASP-8 Mutation Recognized by Cytolytic T Lymphocytes on a Human Head and Neck Carcinoma , 1997, The Journal of experimental medicine.

[20]  S. Baylin.  Mechanisms underlying epigenetically mediated gene silencing in cancer. , 2002, Seminars in cancer biology.

[21]  S. Korsmeyer,et al.  BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. , 2001, Molecular cell.

[22]  S. Korsmeyer,et al.  Proapoptotic BAX and BAK: A Requisite Gateway to Mitochondrial Dysfunction and Death , 2001, Science.

[23]  P. Galle,et al.  Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. , 1997, The Journal of clinical investigation.

[24]  G. Landes,et al.  Analysis of human transcriptomes , 1999, Nature Genetics.

[25]  P. Scheurich,et al.  TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy , 2002, Apoptosis.

[26]  J. Herman,et al.  Clustering of hypermethylated genes in neuroblastoma , 2003, Genes, chromosomes & cancer.

[27]  P. Krammer,et al.  FLICE-Inhibitory Proteins: Regulators of Death Receptor-Mediated Apoptosis , 2001, Molecular and Cellular Biology.

[28]  S. Fulda,et al.  Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system , 1998, International journal of cancer.

[29]  V. Dixit,et al.  Apoptosis control by death and decoy receptors. , 1999, Current opinion in cell biology.

[30]  I. Herr,et al.  Cellular stress response and apoptosis in cancer therapy. , 2001, Blood.

[31]  A. Giaccia,et al.  Epigenetic changes in tumor Fas levels determine immune escape and response to therapy. , 2002, Cancer cell.

[32]  M. Hengartner.  The biochemistry of apoptosis , 2000, Nature.

[33]  P. Hersey,et al.  Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. , 1999, Cancer research.

[34]  P. Krammer,et al.  The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. , 2000, Experimental cell research.

[35]  P. Krammer,et al.  Immune escape of tumors: apoptosis resistance and tumor counterattack , 2002, Journal of leukocyte biology.

[36]  G. Kroemer,et al.  Chemotherapy: targeting the mitochondrial cell death pathway , 2002, Oncogene.

[37]  Michael Karin,et al.  NF-kappaB in cancer: from innocent bystander to major culprit. , 2002, Nature reviews. Cancer.

[38]  Rachel L. Allen,et al.  Defying death after DNA damage , 2000, Nature.

[39]  S. Cory,et al.  The Bcl2 family: regulators of the cellular life-or-death switch , 2002, Nature Reviews Cancer.